Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate

Por um escritor misterioso

Descrição

Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
PDF] Structure-based design, synthesis, and biological evaluation
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Frontiers Urea-based anticancer agents. Exploring 100-years of
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Development of an online p38α mitogen-activated protein kinase
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
PDF) p38 Kinase inhibitors for the treatment of arthritis and
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Novel strategies for inhibition of the p38 MAPK pathway: Trends in
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Structure-based design, synthesis and biological evaluation of N
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from
de por adulto (o preço varia de acordo com o tamanho do grupo)